Business
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
FEATURED STORIES
Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Elizabeth Holmes, the founder and former CEO of Theranos, has been found guilty of bilking hundreds of millions of dollars from investors to prop up her company.
Biogen exercised an option to pick up an exclusive global license for a drug to treat spinal muscular atrophy from Ionis. The compound, BIIB115, is an antisense oligonucleotide.
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
Data from pre-clinical studies show that OV350 may be developed to treat multiple types of epilepsy and other CNS conditions, including neurodevelopmental diseases.
Right now, Kidd’s focus is on ensuring the company is ready for late-stage development and commercialization activities.
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
Pfizer made an upfront payment of $8 million to Codex DNA. Additionally, the latter is eligible for milestone payments of up to $90 million in clinical milestone payments.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The two companies are already looking at the coming year and seeing the potential for their experimental treatment ofATTR, Eplontersen, formerly known as IONIS-TTR-L.
When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.